Products
New Technology for Respiratory Medicines
 |
Prosonix, Oxford/UK, has launched UMAX, a new disruptive particle engineering technology to be used in respiratory medicine. The proprietary technology delivers unique crystalline, excipient free, highly performing, stable drug particles, that offer significant and distinct and quantifiable advantages over current industry practice, and now enables the development and optimisation of a wide range of mono and combination inhalation therapies independent of delivery platform or device.
Successfully demonstrated on over 30 generic and novel drug molecules and combinations, customer demand is driving a rapid commercialisation program, with the expectation of full scale cGMP production being available later in 2010.
Critically the new UMAX approach does not utilise destructive high energy milling classically used in the preparation of inhalation medicines. This methodology introduces significant variability into drug product and formulation performance with respect to delivered dose, dose content uniformity, dose-to-dose variation, and restricts product shelf life. In addition UMAX does not require the use of any Force Control Agents or exotic excipients in the formation of its' unique crystalline constructs, offering significant benefits in ease of formulation and device reliability, and removing potential safety concerns over long term exposure to chemical additives.
Commenting on the launch, David Hipkiss, CEO of Prosonix said "We are developing and enabling a portfolio of engineered pharmaceutical mono and combination inhalation therapy products that offer distinct and high value advantages to patients, healthcare providers and payors alike."
Keywords : drug delivery drug particles inhalation therapy particle engineering technology Prosonix respiratory medicine
Prosonix Ltd.
Robert Robinson Avenue 1
OX4 4GA Oxford
UK
Tel: +44 1865 784250
Fax: +44 1865 784251
Web: www.prosonix.co.uk
- Legal
- Help
- Participate
- Related Publications
Reader comments (0)